Physician profile
Tamara Graham
NPI 1972953321
$1,750.34
in general payments reported to CMS, 2019-2025
13 companies · $513 in 2025
The $513 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $465 · 2023: $271 · 2024: $502 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.41 | 2022-2025 | |
| Novo Nordisk INC | $293.54 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Ultragenyx Pharmaceutical INC. | $240.74 | 2022 | |
| Genzyme Corporation | $132.00 | 2024 | |
| Evoke Pharma, INC. | $124.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $103.78 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.25 | 2022 | |
| Indivior INC. | $42.84 | 2025 | Sublocade |
| Alkermes, INC. | $33.37 | 2025 | Vivitrol |
| Gilead Sciences, INC. | $26.19 | 2025 | |
| Scpharmaceuticals INC. | $23.81 | 2024 | |
| Lilly USA, LLC | $17.35 | 2024 | Jardiance, Zepbound |
| Braeburn INC. | $16.07 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.